On July 26, the National Health Surveillance Agency (Anvisa) received a request for temporary authorization of emergency use for the vaccine against Covid-19 from the company Sinopharm, forwarded by Blau Farmacêutica, which represents the Chinese laboratory in Brazil.
The period of approval of the vaccine by Anvisa can last up to 30 days. Clinical research on the immunizing agent was developed in countries such as Argentina, Peru, the United Arab Emirates, Egypt and China.
+ São Paulo City Hall anticipates vaccination for 25 years; check the calendar
+ JBS USA negotiates with unions possible mandatory vaccination against Covid for employees
Sinopharm’s vaccine is made from an inactivated virus.
The immunizing agent is applied in two doses, with an interval of three to four weeks between them.
Population that can receive the vaccine
The product is recommended for people over 18 years of age.
Approved by WHO
The immunizing agent was approved for emergency use by the World Health Organization (WHO) in May this year.
According to WHO, the available data on the vaccine in pregnant women are insufficient to assess its efficacy and associated risks in pregnancy. However, the entity recommends immunization in this group – as it is a vaccine that has the virus inactivated – as well as in lactating women.
A phase 3 trial in several countries showed that after completing the immunization cycle, that is, with two doses, there is an efficacy of 79% against symptomatic SARS-CoV-2 infection, this after 14 or more days after the second dose. The effectiveness against hospitalization also received the same effectiveness, 79%.
WHO says Sinopharm’s vaccine has mild and moderate adverse events, and that the most common are pain at the injection site, headache, and fatigue.
+ Learn about the effectiveness of each vaccine against Covid-19